Ward Z, Reynolds R, Campbell L, et al. - In view of the observation that hepatitis C virus (HCV) infection in nearly 50% of people who inject drugs (PWID), a high-risk group for HCV infection, remain undiagnosed in England and their linkage-to-care is poor, researchers examined the cost-effectiveness of an intervention (HepCATT) to increase case-finding and referral to HCV treatment compared with standard-of-care pathways in drug treatment centers (DTCs) in England. They examined PWID attending DTCs in the setting of England specific epidemic with a 40% prevalence of chronic HCV among PWID. For decreasing HCV incidence among PWID, increasing HCV infection case-finding and treatment referral in drug treatment centers could be a highly cost-effective strategy. Observations suggest that over 50-years per 1,000 PWID, 75 (95% central interval 37-129) deaths and 1,330 (827-2,040) or 51% (30-67%) of all new infections could be averted via implementing the HepCATT intervention. Estimates suggest the mean incremental cost-effectiveness ratio of £7,986 per quality-adjusted life-year (QALY) gained, with all probabilistic sensitivity analyses simulations being cost-effective at a £20,000 per QALY willingness-to-pay threshold. As per univariable sensitivity analyses, the intervention would become cost-saving if the cost of HCV treatment decreases to £3,900. If scaled up to all PWID in England, the estimated cost of implementing intervention would be £8.8 million and the decrease in incidence would be by 56% (33-70%) by 2030.